Double Filtration Plasmapheresis Combined With Chemotherapy

Fuling Zhou

Status and phase

Enrolling

Phase 1

Conditions

Multiple Myeloma

Treatments

Combination Product: DFPP combined with chemotherapy

Study type

Interventional

Funder types

Other

Identifiers

NCT04836871

Details and patient eligibility

About

Evaluation of double filtration plasmapheresis combined with chemotherapy for the treatment of abnormalities of M protein or renal function due to the multiple myeloma.

Enrollment

20 estimated patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Multiple myeloma patients who are diagnosed by bone marrow morphology and immunology
Patients with stable condition after conventional treatment
Patients with renal insufficiency or abnormal M protein
Patients over 18 years of age
Liver function: blood bilirubin ≤ 35μmol/L, enzymes aspartate transaminase (AST)/aka alanine aminotransferase (ALT) is less than 2 times the upper limit of normal
Normal heart function
Physical condition score 0-2 level (ECOG score)
Obtain an informed consent form signed by the patient or family member

Exclusion criteria

Allergies or obvious contraindications to any of the drugs involved in the plan
Severe heart disease, including myocardial infarction and cardiac insufficiency.
Suffering from other organ malignancies
Active tuberculosis patients and HIV-positive patients
At the same time suffering from other blood system diseases
Pregnant or lactating women
Able to understand or follow the research plan
Past history of intolerance or allergy to similar drugs
Patients under 18 years of age
Participating in other clinical researchers at the same time
There are any other circumstances that hinder the progress of the research